The First International Symposium on Cancer in People with Intellectual Disability, in February 2014 in Montpellier, France, brought together professionals from various specialties to create exchange ideas and create new collaborations. Building on the success of the first workshop, we announce plans for the Second International Symposium on Cancer in People with Intellectual Disability, scheduled for October 10-12, 2018 in Montpellier, France.
The symposium aims at assembling diverse participants—oncologists, nurses, biologists, researchers, epidemiologists, professional caregivers, psychiatrists, psychologists, anthropologists and family members—dedicated to uncovering issues surrounding the occurrence of cancer in this population.
The only international one of its kind, this symposium offers a unique opportunity to present advances and progress on this poorly understood subject. It is an opportunity to meet professionals from a range of countries and specialties and to open our minds to different approaches, a feature much appreciated at the 2014 symposium.
The program includes the following topics linked with intellectual disability: cancers in children, adults, and older people; experience of cancer in people with intellectual disabilities; cancer epidemiology; organs at risk; genetics; cancer screening and prevention; cancer diagnosis; pain management; palliative care; communicating with persons with intellectual disability and communicating tools; and professional caregivers and cancer.
Contact and organization :
Dr Daniel Satgé, Coordianator
Sarah Habib-Hadef, Clinical Research Associate
symposium2018@oncodefi.org
Secretary : +33(0)983788513
Cancers developed by persons with intellectual disability are poorly understood and different from those in the general population. For psychological and biological reasons, the treatment of these cancers is more difficult.
ONCODEFI , the meeting place of two previously distinct medical fields , namely cancer and intellectual disability, is an original project, the first one ever to have been launched in France or Internationally.
It covers 7,000 new patients each year in France, 35,000 new patients in the USA and over 800,000 in the world.
